Ophthalmology

A panel of eye care specialists review the 4 currently available anti-VEGF agents available for the treatment of wet AMD.

Eye screening varied from 31.8% - 73.0%, with lower screening rates at smaller health systems.

From a new heart failure indication to a first-of-its-kind rare disease treatment, here's the most interesting PDUFA dates for the first half of the year.

Optical treatment with DIMS was significantly associated with slower myopia progression compared to SVL treatment during the lockdown period.

The study suggests a platform that can be integrated into surgical ophthalmic microscopes can provide real-time audiovisual feedback to the surgeon during phacoemulsification cataract surgery.

Roger A. Goldberg, MD, MBA, discusses the evolution of therapy from pre– to post–anti-VEGF agents for patients with wet AMD.

Lloyd Clark, MD, leads the discussion on the goals of therapy for patients with wet AMD and the role of anti-VEGF agents for treatment.

Expert perspectives on the ongoing unmet needs in the management of macular edema following retinal vein occlusion.

Experts reflect on the role of steroids in macular edema following retinal vein occlusion and discuss the limited benefit of combination therapy.

Two experts discuss real-world treatment and observation of patients with macular edema after retinal vein occlusion.

Data show the persistence of fluid at 52 and 100 weeks was associated with worse VA, compared with eyes with recurrent ME or persistently dry macula.

Data show 38% of young adults in the study population experienced a myopia shift of 0.50 D or more in at least 1 eye over 8 years.

Anomaly detection techniques useful in identifying images with and without referable diabetic retinopathy when abnormal data were not available for training of retinal diagnostic systems.

A panel of eye care specialists review tests used in clinical practice to screen patients for wet AMD and comment on the clinical benefit of early intervention in patients.

Lloyd Clark, MD, leads the discussion on the differential diagnosis of wet AMD and the optimal approach to an accurate diagnosis.

Experts consider when they would use specific VEGF inhibitors for patients with macular edema following retinal vein occlusion.

Shared insight on clinical trial data in macular edema following retinal vein occlusion that support use of VEGF inhibition.

Data show In 16 of 17 ophthalmic condition categories, North American Native individuals had significantly different claim rates from non-Hispanic White individuals.

Ehsan Rahimy, MD, and Joseph M. Coney, MD, review the available treatment options for diabetic macular edema.

A professor of ophthalmology describes how concomitant conditions with diabetic macular edema affect the urgency of treatment regimens.

A panel of experts explains how diabetic macular edema progresses over time and how to educate patients about progression prevention.

Dr Theodore Leng reviews the preferred testing options for diabetic macular edema.

Patients in a racial and ethnic minority group were less likely to state they were treated with respect by their clinician compared with non-Hispanic White patients (AOR, 0.77).

Engagement had positive associations with higher comfort with technology, visual acuity, nAMD diagnosis, and the number of intravitreal injections.

A broad scope of treatment options used in the management of macular edema following retinal vein occlusion.